Evotec Trials - LARVOL Sigma

47 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi

NCT03603509: Gene Signatures of Influenza Vaccine Responses in Older Adults

Completed

241

Fluad Vaccine, adjuvanted influenza vaccine, Fluzone High-Dose, high dose influenza vaccine

Mayo Clinic, National Institute of Allergy and Infectious Diseases (NIAID)

Influenza

01/19

NCT03694808: FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

Completed

478

Fluad Vaccine, Fluzone HD Vaccine

David H. Canaday, Case Western Reserve University, US Department of Veterans Affairs, Brown University, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)

Flu

01/23

NCT05007041: Simultaneous RZV and aIIV4 Vaccination

Completed

267

FLUAD® Quadrivalent, Influenza Vaccine, Adjuvanted (Quadrivalent), aIIV4, Fluzone® High-Dose Quadrivalent, High-Dose Quadrivalent Influenza Vaccine, HD-IIV4, SHINGRIX®, Zoster Vaccine Recombinant, Adjuvanted (RZV)

Duke University, Centers for Disease Control and Prevention, Johns Hopkins University

Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event

03/23

06/23

NCT04080531: Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Completed

165

Pneumococcal 13-valent Conjugate Vaccine, PCV13, Prevnar 13, Trivalent Influenza Vaccine, Flu shot, Flu vaccination, Fluzone, Fluzone HD, Fluzone High-dose, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV

Emory University, Sanofi, National Institutes of Health (NIH), National Cancer Institute (NCI)

Plasma Cell Neoplasm

05/21

12/22

NCT04101838: B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Recruiting

Fluzone, influenza vaccine, Flucelvax, Fluzone High-Dose, high dose influenza vaccine, Fluad, adjuvanted influenza vaccine

University of Alabama at Birmingham

Influenza

05/26

NCT06506812: Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes

Not yet recruiting

450000

High-Dose Influenza Vaccine, Standard-Dose Influenza Vaccine

Tor Biering-Sørensen, Sanofi, Hospital Clinico Universitario de Santiago

Influenza

02/26

DANFLU-2, NCT05517174: A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults

Active, not recruiting

339700

Europe

High-Dose Quadrivalent Influenza Vaccine, QIV-HD, Standard-Dose Quadrivalent Influenza Vaccine, QIV-SD

Tor Biering-Sørensen, Sanofi, Statens Serum Institut

Influenza

05/25

08/25

NCT04487041: Tfh Dysfunction in HIV and Aging

Recruiting

400

Standard dose influenza vaccination, Fluzone quadrivalent, High dose influenza vaccination, Fluzone high dose quadrivalent

University of Miami

Human Influenza

06/26

12/26

PIVOT, NCT03330132: Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

Active, not recruiting

1861

RoW

Standard inactivated influenza vaccine (NH formulation), MF 59 adjuvanted inactivated influenza vaccine (NH formulation), High-dose inactivated influenza vaccine (NH formulation), Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

The University of Hong Kong, Centers for Disease Control and Prevention

Influenza, Human

12/25

12/26

FluVax3, NCT05518500: A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

Recruiting

Flu Vaccine (Year 1), Fluzone® Quadrivalent High-Dose, Flu Vaccine (Year 2), FLUAD, Flu Vaccine (Year 3), Flublok Quadrivalent

The Jackson Laboratory, UConn Health, Icahn School of Medicine at Mount Sinai, Weill Medical College of Cornell University, University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID)

Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response

12/26

2021-003953-43: COVID-19: A Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older

Ongoing

1680

Europe

Ad26.COV2.S, Afluria Quadrivalent, Fluzone High-Dose Quadrivalent, VAC31518, Suspension for injection, Suspension for injection in pre-filled syringe, Afluria Quadrivalent, Fluzone High-Dose Quadrivalent

Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V., Biomedical Advanced Research and Development Authority (BARDA)

Healthy Volunteers (Prevention of COVID-19 and influenza), Healthy Volunteers (Prevention of COVID-19 and influenza), Diseases [C] - Virus Diseases [C02]

2019-001401-25: Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Not yet recruiting

121000

Europe

quadrivalent influenza vaccine high dose, VaxigripTetra, J07BB, Suspension for injection in pre-filled syringe, Efluelda, VaxigripTetra

Sanofi Pasteur Inc., Sanofi Pasteur

Prevention of influenza infection in adults from 65 years of age and older, Active immunisation of adults from 65 years of age and older againstinfluenza infection, Diseases [C] - Virus Diseases [C02]

NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

Recruiting

4000

RoW

Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP

The University of Hong Kong

Influenza

09/22

03/23

IGNITE P303, NCT05827978: Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Completed

8422

mRNA-1010, Seasonal influenza vaccine, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine, Fluarix Quadrivalent, Fluzone HD

ModernaTX, Inc.

Seasonal Influenza

06/24

NCT06060457: A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Completed

1900

Placebo, mRNA-1345, Fluzone HD

ModernaTX, Inc.

Respiratory Syncytial Virus

06/24

NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting

9320

RoW

CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD

Novavax

COVID-19

05/25

02/26

2019-001974-27: Reducing the Burden of Influenza after Solid-Organ Transplantation: the STOP-FLU trial Reducción de la carga de enfermedad por gripe tras un trasplante de órganos sólidos: ensayo clínico STOP-FLU

Not yet recruiting

2/3

780

Europe

Suspension for injection in pre-filled syringe, Solution for injection in pre-filled syringe, VaxigripTetra®, Fluad®, Fluzone High Dose®

Centre Hospitalier Universitaire Vaudois (CHUV), Swiss National Science Foundation

Influenza in solid organ transplant patients Gripe en pacientes con trasplante de órgano sólido, Influenza in solid organ transplant patients Gripe en pacientes con trasplante de órgano sólido, Diseases [C] - Virus Diseases [C02]

NCT06482359: Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

Withdrawn

2/3

1925

coformulated CIC Vaccine, SARS-CoV-2 rS, tNIV, Matrix-M adjuvant, Fluzone HD trivalent

Novavax

COVID-19, Influenza

11/25

05/26

2021-003170-31: Feasibility of Conducting a Study Comparing High-Dose Influenza Vaccines to Standard-Dose Influenza Vaccines in Danish Citizens Aged 65-79 Years

Not yet recruiting

40000

Europe

High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine, Suspension for injection in pre-filled syringe, Efluelda®, Standard-Dose Quadrivalent Influenza Vaccine

Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital, Sanofi Pasteur

Prevention of influenza infection in adults aged 65-79 years, Active immunisation of adults aged 65-79 years againstinfluenza infection, Diseases [C] - Virus Diseases [C02]

NCT04613206: High Vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

Active, not recruiting

396

High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone

Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, University of Washington

Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant

07/25

04/26

NCT05291676: Systems Investigation of Vaccine Responses in Aging and Frailty

Recruiting

Fluzone, Fluad

Yale University, National Institute of Allergy and Infectious Diseases (NIAID)

Influenza

04/27

NCT05215327: High Vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Recruiting

270

High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone

Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, Duke University, University of Washington

Immunization; Infection, Transplantation Infection, Influenza

07/27

12/27

PSOT, NCT05947071: High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Recruiting

312

Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone, High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose

National Institute of Allergy and Infectious Diseases (NIAID), Children's Hospital Medical Center, Cincinnati, Lucile Packard Children's Hospital, University of Pittsburgh, Ann & Robert H Lurie Children's Hospital of Chicago, Baylor College of Medicine, Children's Mercy Hospital Kansas City, Children's Healthcare of Atlanta

Immunization; Infection, Transplantation Infection, Influenza

07/27

09/27

NCT05553301: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Completed

1/2

560

Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Flublok Quadrivalent®, Quadrivalent Influenza Standard Dose Vaccine, Fluzone Qudrivalent®, Quadrivalent Influenza High-Dose Vaccine, Fluzone High-Dose Quadrivalent®

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

01/24

NCT05650554: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Completed

1/2

682

US, RoW

Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Flublok Quadrivalent®, Quadrivalent Influenza Standard Dose Vaccine, Fluzone Qudrivalent®, Quadrivalent Influenza High-Dose Vaccine, Fluzone High-Dose Quadrivalent®

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

04/24

NCT05624606: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Completed

1/2

682

Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Flublok Quadrivalent®, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Fluzone Quadrivalent®, Quadrivalent Inactivated Influenza High Dose QIV-HD, Fluzone High-Dose Quadrivalent®

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

03/24

NCT06361875: A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Completed

1/2

910

US, RoW

Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Fluzone Qudrivalent®, Quadrivalent Influenza High-Dose Vaccine, Fluzone High-Dose Quadrivalent®, Quadrivalent Recombinant Influenza Vaccine, Flublok Quadrivalent®

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

06/25

NCT06744205: A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Active, not recruiting

1/2

1162

US, RoW

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Fluzone Qudrivalent®, Quadrivalent Influenza Vaccine High Dose, Fluzone High-Dose Quadrivalent®

Sanofi Pasteur, a Sanofi Company

Influenza, Healthy Volunteers

04/26

SLVP033, NCT03312699: Effects of Aging on Primary and Secondary Vaccine Responses

Completed

Fluzone® quadrivalent, IIV4 inactivated influenza vaccine, Fluzone High Dose, High Dose Trivalent, inactivated influenza vaccine (TIV), Fluad, Adjuvanted Trivalent, inactivated influenza vaccine, Vaqta, Inactivated Hepatitis A Vaccine, Typhim Vi, Typhoid Vi Polysaccharide Vaccine, Vivotif, Typhoid Vaccine Live Oral Ty21a

Stanford University, National Institute of Allergy and Infectious Diseases (NIAID)

Influenza, Hepatitis A, Typhoid, Healthy Adults

12/23

NCT05426174: Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Completed

233

mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine, Fluzone HD

Sanofi Pasteur, a Sanofi Company

Influenza Immunization, Healthy Volunteers

01/24

NCT06229392: A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Recruiting

Fluzone Quadrivalent

Rush University Medical Center

Breast Cancer, Breast Cancer Triple Negative

12/25

NCT06059456: Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Completed

N/A

2078

Europe

Quadrivalent Influenza Vaccine, VaxigripTetra®, High-Dose Quadrivalent Influenza Vaccine, Efluelda®

Sanofi

Influenza Immunization (Healthy Volunteers)

12/23

CHRONOVAX, NCT06088563: Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX

Completed

N/A

Europe

Vaccine injection, EFLUELDA - Fluzone High-Dose Quadrivalent

Centre Hospitalier Universitaire de Nice

Vaccination; Infection

06/24

NCT06029933: Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Recruiting

N/A

960000

Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), Fluad, High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4), Fluzone High-Dose

Kaiser Permanente, Seqirus

Influenza, Community-acquired Pneumonia, Cardiovascular Events

05/25

05/26

NCT05663463: Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Recruiting

N/A

100

Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD

University of Minnesota

Solid Organ Transplant

09/25

12/25

NCT06694025: Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.

Recruiting

N/A

670

RoW

Efluelda Tetra Pre-filled syringe

Sanofi

Immunization, Influenza (Healthy Volunteers)

12/30

EXS21546 / Evotec, Recursion Pharma

NCT05920408 / 2022-001385-35: Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Terminated

1b/2a

Europe

EXS21546

Exscientia AI Limited, Biotrial

Advanced Solid Tumours

09/23

10/23

2022-001385-35: A phase 1b/2a study to assess the safety, tolerability, pharmacokinetic and anti-tumoural activity of EXS21546 in combination with PD-1 inhibitor in patients with advanced solid tumours.

Not yet recruiting

1/2

110

Europe

EXS21546 50mg, EXS21546 100mg, EXS21546 250mg, Capsule

Exscientia AI Limited, Exscientia AI Limited

Solid advanced tumours, Solid advanced tumours, Diseases [C] - Cancer [C04]

IDG16177 / Evotec, Ildong

NCT04982705: IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Recruiting

Europe

[Part 1.1] IDG-16177, [Part 1.1] Placebo of IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177, [Part 2] IDG-16177, [Part 1.2] Placebo of IDG-16177, [Part 2] Placebo of IDG-16177

IlDong Pharmaceutical Co Ltd

Type 2 Diabetes

11/22

12/22

EVT801 / Kazia

NCT05114668: Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients with Advanced Solid Tumours

Active, not recruiting

Europe

EVT801

Kazia Therapeutics Limited

Solid Tumor, Adult

04/25

06/25

BAY 2395840 / Bayer, Evotec

2021-001392-17: A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve pain.

Not yet recruiting

Europe, RoW

BAY 2395840 tablets 150 mg, BAY 2395840, Film-coated tablet

Bayer AG, Bayer AG

Neuropathic pain associated with diabetic peripheral neuropathy, Diabetic nerve pain, is a condition caused by nerve damage due to diabetes., Diseases [C] - Nervous System Diseases [C10]

NCT05563454: A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants

Completed

Japan

BAY2395840

Bayer

Diabetic Neuropathic Pain, Healthy Volunteers

02/23

NCT05406219: A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function

Withdrawn

BAY2395840

Bayer

Diabetic Neuropathic Pain, Renal Impairment, Healthy Volunteers

08/23

10/23

BMS-986419 / BMS

NCT05847439: A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Completed

[14C]BMS-986419, BMS-986419, EOAI4018683

Bristol-Myers Squibb

Healthy Volunteers

07/23

NCT05932277: A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Completed

BMS-986419, Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, Fexofenadine

Bristol-Myers Squibb

Healthy Volunteers

09/23

NCT05963932: A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

Completed

BMS-986419 DR Capsule, BMS-986419 IR Tablet

Bristol-Myers Squibb

Healthy Volunteers

10/23

NCT06846866: A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

Recruiting

BMS-986419, BMS-986419 Matching Placebo, Moxifloxacin, Moxifloxacin Matching Placebo

Bristol-Myers Squibb

Healthy Volunteers

06/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi

NCT03603509: Gene Signatures of Influenza Vaccine Responses in Older Adults

Completed

241

Fluad Vaccine, adjuvanted influenza vaccine, Fluzone High-Dose, high dose influenza vaccine

Mayo Clinic, National Institute of Allergy and Infectious Diseases (NIAID)

Influenza

01/19

NCT03694808: FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

Completed

478

Fluad Vaccine, Fluzone HD Vaccine

Flu

01/23

NCT05007041: Simultaneous RZV and aIIV4 Vaccination

Completed

267

Duke University, Centers for Disease Control and Prevention, Johns Hopkins University

Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event

03/23

06/23

NCT04080531: Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Completed

165

Emory University, Sanofi, National Institutes of Health (NIH), National Cancer Institute (NCI)

Plasma Cell Neoplasm

05/21

12/22

NCT04101838: B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Recruiting

Fluzone, influenza vaccine, Flucelvax, Fluzone High-Dose, high dose influenza vaccine, Fluad, adjuvanted influenza vaccine

University of Alabama at Birmingham

Influenza

05/26

NCT06506812: Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes

Not yet recruiting

450000

High-Dose Influenza Vaccine, Standard-Dose Influenza Vaccine

Tor Biering-Sørensen, Sanofi, Hospital Clinico Universitario de Santiago

Influenza

02/26

DANFLU-2, NCT05517174: A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults

Active, not recruiting

339700

Europe

High-Dose Quadrivalent Influenza Vaccine, QIV-HD, Standard-Dose Quadrivalent Influenza Vaccine, QIV-SD

Tor Biering-Sørensen, Sanofi, Statens Serum Institut

Influenza

05/25

08/25

NCT04487041: Tfh Dysfunction in HIV and Aging

Recruiting

400

Standard dose influenza vaccination, Fluzone quadrivalent, High dose influenza vaccination, Fluzone high dose quadrivalent

University of Miami

Human Influenza

06/26

12/26

PIVOT, NCT03330132: Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

Active, not recruiting

1861

RoW

The University of Hong Kong, Centers for Disease Control and Prevention

Influenza, Human

12/25

12/26

FluVax3, NCT05518500: A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

Recruiting

Flu Vaccine (Year 1), Fluzone® Quadrivalent High-Dose, Flu Vaccine (Year 2), FLUAD, Flu Vaccine (Year 3), Flublok Quadrivalent

Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response

12/26

2021-003953-43: COVID-19: A Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older

Ongoing

1680

Europe

Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V., Biomedical Advanced Research and Development Authority (BARDA)

Healthy Volunteers (Prevention of COVID-19 and influenza), Healthy Volunteers (Prevention of COVID-19 and influenza), Diseases [C] - Virus Diseases [C02]

Not yet recruiting

121000

Europe

quadrivalent influenza vaccine high dose, VaxigripTetra, J07BB, Suspension for injection in pre-filled syringe, Efluelda, VaxigripTetra

Sanofi Pasteur Inc., Sanofi Pasteur

NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

Recruiting

4000

RoW

Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP

The University of Hong Kong

Influenza

09/22

03/23

IGNITE P303, NCT05827978: Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Completed

8422

mRNA-1010, Seasonal influenza vaccine, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine, Fluarix Quadrivalent, Fluzone HD

ModernaTX, Inc.

Seasonal Influenza

06/24

Completed

1900

Placebo, mRNA-1345, Fluzone HD

ModernaTX, Inc.

Respiratory Syncytial Virus

06/24

NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting

9320

RoW

Novavax

COVID-19

05/25

02/26

Not yet recruiting

2/3

780

Europe

Suspension for injection in pre-filled syringe, Solution for injection in pre-filled syringe, VaxigripTetra®, Fluad®, Fluzone High Dose®

Centre Hospitalier Universitaire Vaudois (CHUV), Swiss National Science Foundation

NCT06482359: Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

Withdrawn

2/3

1925

coformulated CIC Vaccine, SARS-CoV-2 rS, tNIV, Matrix-M adjuvant, Fluzone HD trivalent

Novavax

COVID-19, Influenza

11/25

05/26

2021-003170-31: Feasibility of Conducting a Study Comparing High-Dose Influenza Vaccines to Standard-Dose Influenza Vaccines in Danish Citizens Aged 65-79 Years

Not yet recruiting

40000

Europe

High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine, Suspension for injection in pre-filled syringe, Efluelda®, Standard-Dose Quadrivalent Influenza Vaccine

Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital, Sanofi Pasteur

Prevention of influenza infection in adults aged 65-79 years, Active immunisation of adults aged 65-79 years againstinfluenza infection, Diseases [C] - Virus Diseases [C02]

NCT04613206: High Vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

Active, not recruiting

396

High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone

Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, University of Washington

Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant

07/25

04/26

NCT05291676: Systems Investigation of Vaccine Responses in Aging and Frailty

Recruiting

Fluzone, Fluad

Yale University, National Institute of Allergy and Infectious Diseases (NIAID)

Influenza

04/27

NCT05215327: High Vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Recruiting

270

High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone

Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, Duke University, University of Washington

Immunization; Infection, Transplantation Infection, Influenza

07/27

12/27

PSOT, NCT05947071: High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Recruiting

312

Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone, High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose

Immunization; Infection, Transplantation Infection, Influenza

07/27

09/27

NCT05553301: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Completed

1/2

560

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

01/24

NCT05650554: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Completed

1/2

682

US, RoW

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

04/24

NCT05624606: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Completed

1/2

682

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

03/24

NCT06361875: A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Completed

1/2

910

US, RoW

Sanofi Pasteur, a Sanofi Company

Influenza Immunization

06/25

NCT06744205: A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Active, not recruiting

1/2

1162

US, RoW

Sanofi Pasteur, a Sanofi Company

Influenza, Healthy Volunteers

04/26

SLVP033, NCT03312699: Effects of Aging on Primary and Secondary Vaccine Responses

Completed

Stanford University, National Institute of Allergy and Infectious Diseases (NIAID)

Influenza, Hepatitis A, Typhoid, Healthy Adults

12/23

NCT05426174: Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Completed

233

mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine, Fluzone HD

Sanofi Pasteur, a Sanofi Company

Influenza Immunization, Healthy Volunteers

01/24

NCT06229392: A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Recruiting

Fluzone Quadrivalent

Rush University Medical Center

Breast Cancer, Breast Cancer Triple Negative

12/25

NCT06059456: Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Completed

N/A

2078

Europe

Quadrivalent Influenza Vaccine, VaxigripTetra®, High-Dose Quadrivalent Influenza Vaccine, Efluelda®

Sanofi

Influenza Immunization (Healthy Volunteers)

12/23

CHRONOVAX, NCT06088563: Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX

Completed

N/A

Europe

Vaccine injection, EFLUELDA - Fluzone High-Dose Quadrivalent

Centre Hospitalier Universitaire de Nice

Vaccination; Infection

06/24

NCT06029933: Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Recruiting

N/A

960000

Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), Fluad, High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4), Fluzone High-Dose

Kaiser Permanente, Seqirus

Influenza, Community-acquired Pneumonia, Cardiovascular Events

05/25

05/26

NCT05663463: Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Recruiting

N/A

100

Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD

University of Minnesota

Solid Organ Transplant

09/25

12/25

NCT06694025: Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.

Recruiting

N/A

670

RoW

Efluelda Tetra Pre-filled syringe

Sanofi

Immunization, Influenza (Healthy Volunteers)

12/30

EXS21546 / Evotec, Recursion Pharma

NCT05920408 / 2022-001385-35: Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Terminated

1b/2a

Europe

EXS21546

Exscientia AI Limited, Biotrial

Advanced Solid Tumours

09/23

10/23

Not yet recruiting

1/2

110

Europe

EXS21546 50mg, EXS21546 100mg, EXS21546 250mg, Capsule

Exscientia AI Limited, Exscientia AI Limited

Solid advanced tumours, Solid advanced tumours, Diseases [C] - Cancer [C04]

IDG16177 / Evotec, Ildong

NCT04982705: IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Recruiting

Europe

[Part 1.1] IDG-16177, [Part 1.1] Placebo of IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177, [Part 2] IDG-16177, [Part 1.2] Placebo of IDG-16177, [Part 2] Placebo of IDG-16177

IlDong Pharmaceutical Co Ltd

Type 2 Diabetes

11/22

12/22

EVT801 / Kazia

NCT05114668: Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients with Advanced Solid Tumours

Active, not recruiting

Europe

EVT801

Kazia Therapeutics Limited

Solid Tumor, Adult

04/25

06/25

BAY 2395840 / Bayer, Evotec

2021-001392-17: A study to learn how safe BAY 2395840 is and how well it works in participants who have diabetic nerve pain.

Not yet recruiting

Europe, RoW

BAY 2395840 tablets 150 mg, BAY 2395840, Film-coated tablet

Bayer AG, Bayer AG

Neuropathic pain associated with diabetic peripheral neuropathy, Diabetic nerve pain, is a condition caused by nerve damage due to diabetes., Diseases [C] - Nervous System Diseases [C10]

Completed

Japan

BAY2395840

Bayer

Diabetic Neuropathic Pain, Healthy Volunteers

02/23

Withdrawn

BAY2395840

Bayer

Diabetic Neuropathic Pain, Renal Impairment, Healthy Volunteers

08/23

10/23

BMS-986419 / BMS

NCT05847439: A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Completed

[14C]BMS-986419, BMS-986419, EOAI4018683

Bristol-Myers Squibb

Healthy Volunteers

07/23

NCT05932277: A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Completed

BMS-986419, Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, Fexofenadine

Bristol-Myers Squibb

Healthy Volunteers

09/23

NCT05963932: A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

Completed

BMS-986419 DR Capsule, BMS-986419 IR Tablet

Bristol-Myers Squibb

Healthy Volunteers

10/23

Recruiting

BMS-986419, BMS-986419 Matching Placebo, Moxifloxacin, Moxifloxacin Matching Placebo

Bristol-Myers Squibb

Healthy Volunteers

06/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites